Please assess the completion status of the following clinical trial:

Trial Title: PRevention of Macular EDema After Cataract Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* All patients undergoing routine phacoemulsification (one eye per patient)~* willing and/or able to comply with the scheduled visits and other study procedures.~* able to communicate properly and understand instructions.~* accepting possible off-label use of intravitreal bevacizumab and/or subconjunctival preservative-free TA.~Exclusion criteria will be different for non-diabetic and diabetic patients. All ophthalmic exclusion criteria are applicable to the study eye only, unless stated otherwise.~General exclusion criteria for participation in this study are:~1. age below 21 years old;~2. participation in another clinical study;~3. post-traumatic cataract;~4. combined surgery;~5. functional monoculus;~6. previous ocular surgery;~7. progressive glaucoma with severe visual field defects, use of anti-glaucomatous medication or steroid-induced IOP elevation that required IOP-lowering treatment;~8. IOP ≥ 25 mmHg;~9. history of any intraocular inflammation or uveitis;~10. history of pseudoexfoliation syndrome, which is expected to cause peroperative complications;~11. history of Fuchs' endothelial dystrophy or cornea guttata 3+;~12. history of retinal vein occlusion;~13. any macular pathology that might influence VA, other than DME;~14. use of intravitreal bevacizumab or ranibizumab in the previous 6 weeks or intravitreal aflibercept in the previous 10 weeks;~15. use of intra- or periocular corticosteroid injection in the previous 4 months;~16. current use of topical NSAIDs or corticosteroids;~17. use of systemic corticosteroids (≥ 20 mg prednisolone or equivalence);~18. history of relevant adverse events, including serious adverse events (SAE), occurring after administration of NSAIDs, acetylsalicylic acid, sodium sulphite, corticosteroids or bevacizumab;~19. contraindications for use of topical NSAIDs, topical or subconjunctival corticosteroids or intravitreal bevacizumab or related drugs;~Non-diabetic patients with a history of CME will be excluded from participation in the study.~Additionally, diabetic patients will be excluded from participation in case of:~1. macular edema with a CSMT ≥450 µm;~2. very severe NPDR or proliferative DR requiring panretinal photocoagulation or vitrectomy;~3. vitreous haemorrhage present during preoperative visit(s);~4. cerebrovascular accident (CVA), myocardial infarction (MI) or other thromboembolic events in the previous 3 months;~5. a history of recurrent thromboembolic events;~6. a history of severe systemic bleeding in the previous 3 months;~7. major surgery in the previous 3 months;~8. history of glaucoma;

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Non diabetics: bromfenac (Type: ACTIVE_COMPARATOR): bromfenac 0.09% eye drops twice daily starting two days before surgery and continuing 2 weeks postoperatively
- Non diabetics: dexamethasone (Type: ACTIVE_COMPARATOR): dexamethasone 0.1% eye drops four times daily starting two days before surgery and continuing four times daily during the first postoperative week and one drop less per day every following week
- Non diabetics: bromfenac & dexamethasone (Type: ACTIVE_COMPARATOR): bromfenac 0.09% eye drops twice daily starting two days before surgery and continuing 2 weeks postoperative \& dexamethasone 0.1% eye drops four times daily starting two days before surgery and continuing four times daily during the first postoperative week and one drop less per day every following week
- Diabetics: eye drops (Type: ACTIVE_COMPARATOR): bromfenac 0.09% eye drops twice daily starting two days before surgery and continuing 2 weeks postoperative \& dexamethasone 0.1% eye drops four times daily starting two days before surgery and continuing four times daily during the first postoperative week and one drop less per day every following week
- Diabetics: eye drops & TA (Type: ACTIVE_COMPARATOR): bromfenac 0.09% eye drops twice daily starting two days before surgery and continuing 2 weeks postoperative \& dexamethasone 0.1% eye drops four times daily starting two days before surgery and continuing four times daily during the first postoperative week and one drop less per day every following week~\& a peroperative subconjunctival injection of 40 mg triamcinolone acetonide (TA, Triesence/Vistrec)
- Diabetics: eye drops & bevacizumab (Type: ACTIVE_COMPARATOR): bromfenac 0.09% eye drops twice daily starting two days before surgery and continuing 2 weeks postoperative \& dexamethasone 0.1% eye drops four times daily starting two days before surgery and continuing four times daily during the first postoperative week and one drop less per day every following week~\& a peroperative intravitreal injection of 1.25 mg bevacizumab (Avastin)
- Diabetics: eye drops, TA & bevacizumab (Type: ACTIVE_COMPARATOR): bromfenac 0.09% eye drops twice daily starting two days before surgery and continuing 2 weeks postoperative, dexamethasone 0.1% eye drops four times daily starting two days before surgery and continuing four times daily during the first postoperative week and one drop less per day every following week~\& a peroperative subconjunctival injection of 40 mg triamcinolone acetonide (TA)~\& a peroperative intravitreal injection of 1.25 mg bevacizumab

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete